Generic Yorvipath Availability
Last updated on Apr 10, 2025.
Yorvipath is a brand name of palopegteriparatide, approved by the FDA in the following formulation(s):
YORVIPATH (palopegteriparatide - solution;subcutaneous)
-
Manufacturer: ASCENDIS PHARMA BONE
Approval date: August 9, 2024
Strength(s): EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML) [RLD], EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML) [RLD], EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML) [RLD]
Is there a generic version of Yorvipath available?
No. There is currently no therapeutically equivalent version of Yorvipath available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Yorvipath. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dosage regimen for a controlled-release PTH compound
Patent 11,590,207
Issued: February 28, 2023
Inventor(s): Holten-Andersen; Lars et al.
Assignee(s): ASCENDIS PHARMA BONE DISEASES A/S (Hellerup, DK)The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.
Patent expiration dates:
- September 28, 2037✓
- September 28, 2037
-
PTH compounds with low peak-to-trough ratios
Patent 11,759,504
Issued: September 19, 2023
Inventor(s): Sprogøe; Kennett et al.
Assignee(s): Ascendis Pharma Bone Diseases A/S (Hellerup, DK)The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.
Patent expiration dates:
- September 28, 2037✓
- September 28, 2037
-
PTH compounds with low peak-to-trough ratios
Patent 11,857,603
Issued: January 2, 2024
Inventor(s): Sprogøe; Kennett et al.
Assignee(s): ASCENDIS PHARMA BONE DISEASES A/S (Hellerup, DK)The present invention relates to a pharmaceutical composition comprising a PTH compound, wherein after subcutaneous administration the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one injection interval.
Patent expiration dates:
- September 28, 2037✓
- September 28, 2037
-
Controlled-release PTH compound
Patent 11,890,326
Issued: February 6, 2024
Inventor(s): Sprogøe; Kennett et al.
Assignee(s): ASCENDIS PHARMA BONE DISEASES A/S (Hellerup, DK)The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
Patent expiration dates:
- September 28, 2037✓✓
- September 28, 2037
-
Controlled-release PTH compound
Patent 11,918,628
Issued: March 5, 2024
Inventor(s): Sprogøe; Kennett et al.
Assignee(s): ASCENDIS PHARMA BONE DISEASES A/S (Hellerup, DK)The present invention relates to a controlled-release parathyroid hormone (PTH) compound in which PTH(1-34) is reversibly conjugated to a branched polyethylene glycol. The invention further relates to a pharmaceutical composition of the compound. The compound or pharmaceutical composition is useful for treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH.
Patent expiration dates:
- September 28, 2037✓✓
- September 28, 2037
-
Prodrug comprising a drug linker conjugate
Patent 8,906,847
Issued: December 9, 2014
Inventor(s): Cleemann Felix & Hersel Ulrich & Kaden Silvia & Rau Harald & Wegge Thomas
Assignee(s): Ascendis Pharma A/SThe present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -Lrepresented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R, R, R, R, R, R, X, X, X, Xhave the meaning as indicated in the description and the claims and wherein Lis substituted with one to four groups L-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein Lis a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.
Patent expiration dates:
- April 30, 2031✓✓✓
- April 30, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- August 9, 2029 - NEW CHEMICAL ENTITY
- August 9, 2031 - TREATMENT OF HYPOPARATHYROIDISM IN ADULTS
More about Yorvipath (palopegteriparatide)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: parathyroid hormone and analogs
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
